ALX Oncology
ALX Oncology is focused on transforming cancer treatment through the development of evorpacept, a next-generation CD47 checkpoint inhibitor designed to maximize clinical activity and minimize toxicities.
Company Overview
ALX Oncology is focused on transforming cancer treatment through its development of evorpacept, a novel checkpoint immunotherapy. The company was established to tackle the fundamental challenges in targeting CD47 and aims to minimize therapeutic toxicities while maximizing clinical benefits. ALX Oncology is committed to unraveling the full potential of CD47 blockade as a pivotal therapeutic approach in oncology.
Lead Product: Evorpacept (ALX148)
ALX Oncology's lead product candidate, evorpacept (ALX148), is an intravenously administered fusion protein specifically designed to block the 'don't eat me' signal on cancer cells. Evorpacept contains two engineered high-affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin. This next-generation checkpoint inhibitor aims to overcome the limitations associated with hematologic toxicities, presenting a safer profile compared to other anti-CD47 molecules with active Fc regions.
Clinical Trials
ALX Oncology is actively conducting multiple clinical trials to evaluate evorpacept's efficacy across various cancer types. These include the ASPEN-06 study for HER2-positive gastric/gastroesophageal junction cancer, ASPEN-03 and ASPEN-04 for head and neck squamous cell carcinoma in combination with KEYTRUDA®, and ASPEN-07 for urothelial carcinoma with Enfortumab Vedotin. Other trials include combination studies with Lenalidomide, Rituximab, and Azacitidine for conditions like non-Hodgkin lymphoma and myelodysplastic syndrome. Evorpacept is being assessed with various anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 inhibitors in these trials.
Mission and Approach
ALX Oncology's mission is to revolutionize cancer treatment by successfully developing evorpacept as a foundational checkpoint immunotherapy. The company aims to overcome the challenges in blocking CD47 to maximize clinical efficacy while reducing toxicities. Their approach involves developing a high-affinity CD47 inhibitor designed to work in combination with widely used anti-cancer agents, thereby enhancing immune activation and therapeutic outcomes.